Dysport

Showing 2 posts of 2 posts found.

Phase 3 trials support expanded use of Dysport for migraine prevention

July 15, 2026
Research and Development Dysport, ipsen, migraine prevention

Ipsen has reported positive topline results from its phase 3 BEOND clinical programme evaluating Dysport (abobotulinumtoxinA) for the prevention of …

MHRA expands approval of Dysport for symptomatic treatment of focal spasticity of the upper limbs in paediatric cerebral palsy

January 6, 2020
Sales and Marketing Dysport, MHRA, ipsen, pharma

Ipsen has secured an expansion in the UK to the existing label for Dysport (lemborexant), with the Medicines and Healthcare …

The Gateway to Local Adoption Series

Latest content